CClinicalTrials.gg
Status unknownNCT03600285EMERGEUpdated Jun 21, 2019

Prospective, Single-Arm, Study to Assess the Safety and Performance of the TB1-K Device for Organ Preservation in Donor Kidneys for Transplantation

An interventional study of TB1-K in Kidney Preservation and Transportation, sponsored by Transplant Biomedicals, S.L.. Status unknown at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Transplant Biomedicals, S.L. · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

TB1-K Device is an organ preservation and transportation system, using ultrasound technology with a cooling system to preserve the organ in optimal conditions during transport to the transplant recipient.

This is a prospective, single-arm, multi-center study comparing to a historical control for cold storage.

The study is conducted in accordance with the Standard ISO 14155 (Clinical investigation of medical devices for human subjects - Good clinical practice), and other legal requirements.

The study objective is to assess the safety and performance of the TB1-K device in donor kidneys intended for transplantation.

02

Conditions studied

  • Kidney Preservation and Transportation

Keywords

  • VIVIAN
03

In context

Lead sponsor

This is the only study on the registry with Transplant Biomedicals, S.L. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Donor Inclusion Criteria:

  1. Donor kidney suitable for preservation
  2. Only one kidney per donor will be included
  3. Cold ischemia time (CIT) ≤ 24 hours
  4. Donor age over 18 years old
  5. Donor meets one of the following:

    1. Donor after brain death (DBD), standard and extended criteria
    2. Donor after circulatory death (DCD), cardiac arrest Maastricht classification III (awaiting cardiac arrest, controlled)
  6. Signed written informed consent

Donor Exclusion Criteria:

  1. Kidney, which investigator is unwilling to use, or presence of moderate or severe traumatic kidney injury, or anatomical kidney vascular abnormalities, which would preclude the organ from being acceptable by the transplant surgeon
  2. Donor after circulatory death (DCD), Maastricht classification I, II, IV, V (See Definitions, section 14)
  3. Living donors
  4. Previous usage of a perfusion machine (PM)
  5. Kidneys not considered suitable for preservations
  6. Positive serology (HIV, Hepatitis B surface antigen \& C)

Recipient Inclusion Criteria:

  1. Registered primary kidney transplant candidate, male or female
  2. Age ≥ 18 years old
  3. Signed written informed consent

Recipient Exclusion Criteria:

  1. Prior solid organ or bone marrow transplant
  2. Multi-organ transplant
  3. Active malignancy
  4. Active infection
  5. Pregnant females, females intending to get pregnant, or not willing to use a secure contraceptive method.
  6. Participation in another clinical trial.
  7. Patient with known donor-specific HLA antibody
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    TB1-K

    TB1-K preservation arm

    Device: TB1-K

Interventions

  • DeviceTB1-K

    Use of TB1-K for preservation and transport of donated kidneys

06

What researchers measure

Primary outcomes

  1. Rate of DGF

    Rate of delayed graft function (DGF), defined as need for dialysis in the first week after transplant, once hyperacute rejection, vascular and urinary tract complications are ruled out.

    Time frame: 1 week after transplant

07

Study locations

3 sites
  • Hospital Unviersitario de Bellvitge
    Barcelona, Hospitalet De Llobregat 08907, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03600285
Lead sponsor
Transplant Biomedicals, S.L.
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Jun 29, 2018
Primary completion
Feb 15, 2019
Completion
Mar 31, 2020 (estimated)
Last update
Jun 21, 2019

Study contacts

Fritz Diekmann, PhD
principal investigator · Hospital Clinic i provincial de Barcelona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion